Kristeen Ye Wen Teo

Dr. Kristeen Ye Wen Teo

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2024 in Cells
Verified
Journal Article
Open access
PDF file
YJYuanyuan Jiang
Yuanyuan Jiang
JSJiajun Shi
Jiajun Shi
WDWenjun Di
Wenjun Di
KTKristeen Ye Wen Teo
Kristeen Ye Wen Teo
WTWei Seong Toh
Wei Seong Toh
Temporomandibular disorders (TMDs) are a heterogeneous group of musculoskeletal and neuromuscular conditions involving the temporomandibular joint (TMJ), masticatory muscles, and associated structures. Mesenchymal stromal/stem cells (MSCs) have emerged as a promising therapy for TMJ repair. This systematic review aims to consolidate findings from the preclinical animal studies evaluating MSC-based therapies, including MSCs, their secretome, and extracellular vesicles (EVs), for the treatment of TMJ cartilage/osteochondral defects and osteoarthritis (OA). Following the PRISMA guidelines, PubMed, Embase, Scopus, and Cochrane Library databases were searched for relevant studies. A total of 23 studies involving 125 mice, 149 rats, 470 rabbits, and 74 goats were identified. Compliance with the ARRIVE guidelines was evaluated for quality assessment, while the SYRCLE risk of bias tool was used to assess the risk of bias for the studies. Generally, MSC-based therapies demonstrated efficacy in TMJ repair across animal models of TMJ defects and OA. In most studies, animals treated with MSCs, their derived secretome, or EVs displayed improved morphological, histological, molecular, and behavioral pain outcomes, coupled with positive effects on cellular proliferation, migration, and matrix synthesis, as well as immunomodulation. However, unclear risk in bias and incomplete reporting highlight the need for standardized outcome measurements and reporting in future investigations.

18 February 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ABAyça Altay Bettini
Ayça Altay Bettini
CNChiew Yong Ng
Chiew Yong Ng
CQCanone Chen Qiuyi
Canone Chen Qiuyi
ASAhmad Suhaimi
Ahmad Suhaimi
YJYuanyuan Jiang
Yuanyuan Jiang
GPGiorgia Pastorin
Giorgia Pastorin
Osteoarthritis is a common and chronic degenerative joint disease that leads to persistent symptoms such as pain, stiffness, swelling, and fatigue, all of which significantly impair mobility and reduce quality of life. Viral infections can further worsen joint inflammation in individuals with pre-existing osteoarthritis. Among these, the chikungunya virus (CHIKV) has become an increasing public health concern, particularly in Asia and South America, where post-viral arthritis frequently mimics or intensifies chronic osteoarthritic symptoms. Current treatments rely mainly on analgesics, corticosteroids, and biologics, which often provide only temporary relief and can cause systemic side effects. Poor bioavailability and limited drug penetration into joint tissues also remain major obstacles to effective long-term therapy. To address these challenges, this study focused on developing a proniosome-based topical gel capable of delivering therapeutic agents locally and in a sustained manner to inflamed joints. The formulation incorporated berberine hydrochloride, Coptis chinensis extract, and glucosamine, selected for their anti-inflammatory and cartilage-protective properties. Non-ionic surfactants and co-lipids were optimized to enhance skin permeation, improve vesicle stability, and support controlled release. Preclinical evaluations were conducted using both osteoarthritis and CHIKV-induced arthritis in vivo models. The optimized proniosome gel demonstrated strong therapeutic efficacy, including reductions in inflammatory markers, improved cartilage preservation and better subchondral bone structure. Importantly, no hepatic or renal toxicity was observed. These findings suggest that the proniosome-based gel offers a safe and effective topical approach for arthritis management, providing localized and sustained drug delivery while minimizing systemic exposure.